a: Sample size re-estimation and enrichment design
b: Marketing authorization was granted to the drug for which clinical
trials at the time were ongoing
c: Marketing authorization was granted to the drug for which clinical
trials at the time were completed
d: Fisher’s exact test was conducted
e: Conditional marketing authorisation, Post-authorisation safety study,
Post-authorisation efficacy study